{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:47:46Z","timestamp":1778694466348,"version":"3.51.4"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA031022"],"award-info":[{"award-number":["R01DA031022"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01DA030446"],"award-info":[{"award-number":["K01DA030446"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"OMEROS Corporation"},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["DA09236"],"award-info":[{"award-number":["DA09236"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["DA030446"],"award-info":[{"award-number":["DA030446"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["DA031022"],"award-info":[{"award-number":["DA031022"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physiology & Behavior"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.physbeh.2015.10.006","type":"journal-article","created":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T00:00:53Z","timestamp":1445212853000},"page":"33-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["The effects of pioglitazone, a PPAR\u03b3 receptor agonist, on the abuse liability of oxycodone among nondependent opioid users"],"prefix":"10.1016","volume":"159","author":[{"given":"Jermaine D.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne M.","family":"Manubay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanthi","family":"Mogali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena E.","family":"Metz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Ciccocioppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra D.","family":"Comer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.physbeh.2015.10.006_bb0005","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.neurobiolaging.2007.04.013","article-title":"Neocortical glial cell numbers in human brains","volume":"29","author":"Pelvig","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0010","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/0166-2236(96)10049-7","article-title":"Microglia: a sensor for pathological events in the CNS","volume":"19","author":"Kreutzberg","year":"1996","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0168-0102(93)90047-T","article-title":"Functional roles of microglia in the brain","volume":"17","author":"Nakajima","year":"1993","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0301-0082(98)00083-5","article-title":"The role of microglia and macrophages in the pathophysiology of the CNS","volume":"58","author":"Stoll","year":"1999","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0025","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0166-2236(96)10048-5","article-title":"Calcium signaling in glial cells","volume":"19","author":"Verkhratsky","year":"1996","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0030","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4049\/jimmunol.123.3.1068","article-title":"Suggestive evidence for receptors for morphine and methionine\u2013enkephalin on normal human blood T lymphocytes","volume":"123","author":"Wybran","year":"1979","journal-title":"J. Immunol."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0035","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3181\/00379727-213-44056","article-title":"The relevance of opioids and opioid receptors on immunocompetence and immune homeostasis","volume":"213","author":"Carr","year":"1996","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0040","unstructured":"Gomez-Flores R., Weber R.J Opioids, opioid receptors, and the immune system. In: Plotnikoff NP, Faith RE, Murgo AJ, Good RA (eds) Cytokines, stress and immunity. CRC Press, Boca Raton, pp 281\u2013314."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-5728(97)00217-8","article-title":"Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism(s) of action","volume":"83","author":"Mellon","year":"1998","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0050","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0891-5520(02)00018-1","article-title":"Opioids immunology and host defenses of intravenous drug abusers","volume":"16","author":"Alonzo","year":"2002","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0055","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0022-3565(25)10181-X","article-title":"Cytokine reversal of morphine-induced suppression of the antibody response","volume":"264","author":"Bussiere","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0060","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0192-0561(93)90143-M","article-title":"Macrophage functions in drugs of abuse-treated mice","volume":"15","author":"Pacifici","year":"1993","journal-title":"Int. J. Immunopharmacol."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0065","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/j.1476-5381.2011.01475.x","article-title":"Depletion and recovery of lymphoid subsets following morphine administration","volume":"164","author":"Zhang","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-8993(94)90899-0","article-title":"Effects of morphine tolerance and abstinence on cellular immune function","volume":"642","author":"Bhargava","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0075","series-title":"Drugs of abuse, immunity and infections","first-page":"103","article-title":"Lawrence D.M.P Immunomodulation by morphine and other opioids","author":"Eisenstein","year":"1996"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0080","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11481-006-9019-1","article-title":"Effects of opioid tolerance and withdrawal on the immune system","volume":"1","author":"Eisenstein","year":"2006","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0085","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbi.2008.09.012","article-title":"Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast)","volume":"23","author":"Hutchinson","year":"2009","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0090","doi-asserted-by":"crossref","first-page":"7353","DOI":"10.1523\/JNEUROSCI.1850-04.2004","article-title":"A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine","volume":"24","author":"Johnston","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0095","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0165-5728(85)80063-1","article-title":"Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes","volume":"8","author":"Eng","year":"1985","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0100","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/sj.npp.1300513","article-title":"Cytoskeletal genes regulation by chronic morphine treatment in rat striatum","volume":"29","author":"Marie-Claire","year":"2004","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0105","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1111\/j.1471-4159.1993.tb09814.x","article-title":"Glial fibrillary acidic protein and the mesolimbic dopamine system: regulation by chronic morphine and Lewis-Fischer strain differences in the rat ventral tegmental area","volume":"61","author":"Beitner-Johnson","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neulet.2005.04.002","article-title":"The alpha2-adrenoceptor antagonist yohimbine reduces glial fibrillary acidic protein upregulation induced by chronic morphine administration","volume":"383","author":"Garrido","year":"2005","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0115","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0168-0102(00)00226-1","article-title":"The involvement of glial cells in the development of morphine tolerance","volume":"39","author":"Song","year":"2001","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0120","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neuropharm.2013.05.039","article-title":"Why is neuroimmunopharmacology crucial for the future of addiction research?","volume":"76","author":"Hutchinson","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0125","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.tins.2005.10.001","article-title":"Glia: novel counter-regulators of opioid analgesia","volume":"28","author":"Watkins","year":"2005","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0130","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1038\/sj.npp.1301007","article-title":"Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse","volume":"31","author":"Narita","year":"2006","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0135","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/13543784.2012.651123","article-title":"Glial Inhibitors: A novel pharmacological approach to modulating the behavioral effects of abused substances","volume":"21","author":"Cooper","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pain.2005.02.009","article-title":"Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation","volume":"115","author":"Ledeboer","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0145","article-title":"Propentofylline: glial modulation, neuroprotection, and alleviation of chronic pain","volume":"200","author":"Sweitzer","year":"2011"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0150","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bbi.2006.07.001","article-title":"Efficacy of propentofylline, a glial modulating agent, on existing mechanical allodynia following peripheral nerve injury","volume":"21","author":"Tawfik","year":"2007","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0155","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.bbi.2009.01.014","article-title":"The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release","volume":"23","author":"Bland","year":"2009","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0160","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1100\/tsw.2007.230","article-title":"Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence and reward","volume":"7","author":"Hutchinson","year":"2007","journal-title":"Sci. World J."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0165","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.brainres.2004.12.003","article-title":"Ciglitazone increases basal cytokine expression in the central nervous system of adult rats","volume":"1034","author":"Gelinas","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuroscience.2003.08.064","article-title":"Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS","volume":"123","author":"Moreno","year":"2004","journal-title":"Neurosci"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0175","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1210\/en.2008-0899","article-title":"Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis","volume":"150","author":"Sarruf","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0180","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0006-8993(03)02515-0","article-title":"Localization of PPARdelta in murine central nervous system: expression in oligodendrocytes and neurons","volume":"975","author":"Woods","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0185","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/jnr.10501","article-title":"Effects of PPARc agonists on central nervous system inflammation","volume":"71","author":"Kielian","year":"2003","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0190","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1111\/bph.12851","article-title":"Analgesic tolerance to morphine is regulated by PPAR\u03b3","volume":"171","author":"de Guglielmo","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0195","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/npp.2014.268","article-title":"PPAR\u03b3 Activation Attenuates Opioid Consumption and Modulates Mesolimbic Dopamine Transmission","volume":"40","author":"de Guglielmo","year":"2015","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0200","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jat\/27.2.57","article-title":"Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases","volume":"27","author":"Cone","year":"2003","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0205","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1503\/cmaj.090784","article-title":"Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone","volume":"181","author":"Dhalla","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0210","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/AJP.0b013e318167a087","article-title":"Internet-based survey of nonmedical prescription opioid use in the United States","volume":"24","author":"Katz","year":"2008","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0215","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1345\/aph.1K013","article-title":"Evolution of peroxisome proliferator-activated receptor agonists","volume":"41","author":"Chang","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0220","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","article-title":"Fat and beyond: the diverse biology of PPAR gamma","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annu. Rev. Biochem."},{"issue":"1-3","key":"10.1016\/j.physbeh.2015.10.006_bb0225","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.drugalcdep.2011.10.018","article-title":"Opioid Challenge Evaluation of Blockade by Extended-Release Naltrexone in Opioid-Abusing Adults: Dose-Effects and Time-Course","volume":"123","author":"Begelow","year":"2012","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.physbeh.2015.10.006_bb0230","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S0022-3565(24)38292-8","article-title":"Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers","volume":"289","author":"Walker","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.physbeh.2015.10.006_bb0235","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s002130100723","article-title":"Subjective, psychomotor, and physiological effects of cumulative doses of mixed-action opioids in healthy volunteers","volume":"155","author":"Walker","year":"2001","journal-title":"Psychopharmascology (Berlin)"},{"issue":"2","key":"10.1016\/j.physbeh.2015.10.006_bb0240","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002130100920","article-title":"Blockade of hydromorphone effects by buprenorphine\/naloxone and buprenorphine","volume":"159","author":"Strain","year":"2002","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0245","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0022-3565(25)21159-4","article-title":"Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans","volume":"279","author":"Walsh","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0250","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/15209150260007381","article-title":"Physiological and therapeutic roles of peroxisome proliferator-activated receptors","volume":"4","author":"Berger","year":"2002","journal-title":"Technol. Ther."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0255","first-page":"343","article-title":"Strategies for analyzing side effect data from Safetee: a workshop held Fall 1985 in Rockville, Maryland","volume":"22","author":"Levine","year":"1986","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0260","article-title":"The AUDIT Alcohol Consumption Questions (AUDIT-C): An effective brief screening test for problem drinking","volume":"1789\u201395","author":"Bush","year":"1998","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0265","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-3565(25)26118-3","article-title":"Methods for evaluating addiction liability. (A) \"Attitude\" of opiate addicts toward opiate-like drugs. (B) a short-term \"direct\" addiction test","volume":"133","author":"Fraser","year":"1961","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0270","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0022-3565(25)26119-5","article-title":"A comparative study of physiological and subjective effects of heroin and morphine administered intravenously in post-addicts","volume":"133","author":"Martin","year":"1961","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0275","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0376-8716(96)01274-4","article-title":"The effects of a cold-water immersion stressor on the reinforcing and subjective effects of fentanyl in healthy volunteers","volume":"42","author":"Zacny","year":"1996","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0280","series-title":"SPSS 18.0.0 for windows","author":"SPSS","year":"2009"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0285","first-page":"191","article-title":"Superanova accessible general linear modeling","volume":"63","author":"Gagnon","year":"1990","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0290","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drugalcdep.2008.05.007","article-title":"The relative abuse liability of oral oxycodone, hydrocodone and hydro-morphine assessed in prescription opioid abusers","volume":"98","author":"Walsh","year":"2008","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0295","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00213-003-1540-9","article-title":"Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non- drug-abusing volunteers","volume":"170","author":"Zacny","year":"2003","journal-title":"Psychopharmacol"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0300","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugalcdep.2008.11.013","article-title":"Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers","volume":"101","author":"Zacny","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0305","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s13181-012-0263-x","article-title":"Likeability and abuse liability of commonly prescribed opioids","volume":"8","author":"Wightman","year":"2012","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0310","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00003495-200060020-00009","article-title":"Pioglitazone","volume":"60","author":"Gillies","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0315","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/10408360091174187","article-title":"Measurement of cytokines in clinical samples using immunoassays: problems and pitfalls","volume":"37","author":"Banks","year":"2000","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0320","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/1742-2094-9-255","article-title":"Cerebrospinal fluid and plasma cytokines after subarachnoid haemorrhage: CSF interleukin-6 may be an early marker of infection","volume":"9","author":"Hopkins","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0325","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.tips.2009.08.002","article-title":"The \u201ctoll\u201d of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia","volume":"30","author":"Watkins","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0330","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1111\/j.1476-5381.2011.01513.x","article-title":"Opioids and the immune system: what is their mechanism of action?","volume":"164","author":"Eisenstein","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0335","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/acer.12091","article-title":"Activation of PPAR\u03b3 by pioglitazone potentiates the effects of naltrexone on alcohol drinking and relapse in msP rats","volume":"37","author":"Stopponi","year":"2013","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.physbeh.2015.10.006_bb0340","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.biopsych.2010.12.010","article-title":"Activation of nuclear PPAR\u03b3 receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking","volume":"69","author":"Stopponi","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.physbeh.2015.10.006_bb0345","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.neuropharm.2014.06.024","article-title":"PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption","volume":"86","author":"Ferguson","year":"2014","journal-title":"Neuropharmacolo"}],"container-title":["Physiology & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031938415301372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031938415301372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T02:11:47Z","timestamp":1748657507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031938415301372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":69,"alternative-id":["S0031938415301372"],"URL":"https:\/\/doi.org\/10.1016\/j.physbeh.2015.10.006","relation":{},"ISSN":["0031-9384"],"issn-type":[{"value":"0031-9384","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of pioglitazone, a PPAR\u03b3 receptor agonist, on the abuse liability of oxycodone among nondependent opioid users","name":"articletitle","label":"Article Title"},{"value":"Physiology & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.physbeh.2015.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}